基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
预处理 TIL（肿瘤浸润淋巴细胞）与接受 CDK4/6 抑制剂治疗的 HR+/HER2-晚期乳腺癌患者预后的关系
英文原题：Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.
查看英文原题
Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
越来越多的证据表明，增强肿瘤免疫反应有助于CDK4/6抑制剂（CDK4/6i）的抗肿瘤活性，但治疗前肿瘤免疫微环境的作用尚不明确。
我们回顾性研究了接受CDK4/6i联合内分泌治疗的HR+/HER2-晚期乳腺癌患者，探讨治疗前间质TIL（肿瘤浸润淋巴细胞）（sTILs）是否与结局相关。共100例患者可评估，其中53例接受palbociclib治疗，44例接受ribociclib治疗，3例接受abemaciclib治疗。当sTILs≥10%时，肿瘤被归类为sTILs阳性（sTILs+）。58例肿瘤为sTILs阴性（sTILs-），42例为sTILs+。sTILs总体上及在ribociclib队列中与任何结局均无关。相反，与sTILs-肿瘤患者相比，接受palbociclib治疗且肿瘤为sTILs+的患者总生存期有统计学显著改善（mOS未达到 vs. 41.1个月，p = .038），且内脏进展风险降低（24例 vs. 8例，p=.0048）。治疗前sTILs水平与接受palbociclib治疗患者的结局相关。鉴于治疗与sTILs之间缺乏交互作用，我们的发现需要在更大规模的独立队列中验证，若得到证实，则建议将sTILs作为一种简单且可重复的生物标志物，用于辅助palbociclib的患者选择。
展开英文摘要原文
Growing evidence suggests that enhancement of the tumor immune response contributes to the antitumor activity of CDK4/6 inhibitors (CDK4/6i), but the role of pretreatment tumor immune microenvironment is not clear.
We retrospectively investigated in patients with HR+/HER2- advanced breast cancer receiving CDK4/6i and endocrine therapy whether pretreatment stromal tumor infiltrating lymphocytes (sTILs) were associated with outcome. A total of 100 patients were evaluable 53 treated with palbociclib, 44 with ribociclib and 3 with abemaciclib. Tumors were classified as sTILs positive (sTILs+) when sTILs were ≥ 10%. 58 tumors were sTILs negative (sTILs-) and 42 sTILs+. sTILs were not associated with any outcome overall and in the ribociclib cohort.
Conversely, patients treated with palbociclib and sTILs+ tumors experienced a statistically significant improved overall survival (mOS Not Reached vs. 41. 1 months, p = . 038) and a reduced risk of visceral progression (24 vs. 8 patients p=. 0048) as compared with patients with sTILs- tumors.
Pretreatment sTILs levels were associated with outcome in patients treated with palbociclib. Given the lack of interaction between treatment and sTILs our findings warrant validation in larger, independent cohorts and if confirmed propose sTILs as a simple and reproducible biomarker to aid patient selection for palbociclib.
论文信息
- 作者
- Torrisi R、Giordano L、Pancetti S、Carnaghi C、Basilico V、Palumbo R、Gerosa R、Saltalamacchia G
- 单位
- IRCCS, Humanitas Research Hospital Medical Oncology and Hematology Unit, viale Manzoni 56, 20089, Rozzano, MI, Italy. roslaba.torrisi@gmail.com.Italy
- 期刊
- Scientific reports2026 Feb 26
- 原文标识
- PubMed 41748816 · DOI 10.1038/s41598-026-40616-1
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →